Tuberculosis: From molecular pathogenesis to effective drug carrier design

Drug Discovery Today

Volumn 17, Issue 13-14, 2012, Pages 760-773

  Dube, Devyani ^a   Agrawal, Govind P ^a   Vyas, Suresh P ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; COMPLEMENT COMPONENT C3B RECEPTOR; CYCLOSERINE; DENDRIMER; DRUG CARRIER; ECONAZOLE; ETHAMBUTOL; GENTAMICIN; ISONIAZID; LIPOSOME; MOXIFLOXACIN; NANOCARRIER; NIOSOME; OFLOXACIN; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; SOLID LIPID NANOPARTICLE; SPARFLOXACIN; STREPTOMYCIN; THIOACETAZONE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; COMBINATION CHEMOTHERAPY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GRANULOMA; HUMAN; INFECTION PREVENTION; LIPOSOMAL DELIVERY; MICELLE; MICROENCAPSULATION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NANOENCAPSULATION; NONHUMAN; PATHOGENESIS; PATIENT COMPLIANCE; REVIEW; SHORT COURSE THERAPY; SINGLE DRUG DOSE; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG CARRIERS; DRUG DESIGN; HUMANS; MICELLES; NANOPARTICLES; POLYMERS; TUBERCULOSIS;

EID: 84863506966     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.03.012     Document Type: Review

References (102)

1. D.F. Warner, and V. Mizrahi Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy Clin. Microbiol. Rev. 19 2006 558 570 (Pubitemid 44134310)
2. S.H. Kaufmann How can immunology contribute to the control of tuberculosis? Nat. Rev. Immunol. 1 2001 20 30 (Pubitemid 33741972)
3. J.A. Armstrong, and P.D. Hart Phagosome-lysosome interactions in cultured macrophages infected with virulent tubercle bacilli. Reversal of the usual nonfusion pattern and observations on bacterial survival J. Exp. Med. 142 1975 1 16
4. D.G. Russell Mycobacterium tuberculosis: here today, and here tomorrow Nat. Rev. Mol. Cell. Biol. 2 2001 569 577 (Pubitemid 33674008)
5. A. Aderem, and D.M. Underhill Mechanisms of phagocytosis in macrophages Annu. Rev. Immunol. 17 1999 593 623 (Pubitemid 29241135)
6. J.D. Ernst Macrophage receptors for Mycobacterium tuberculosis Infect. Immun. 66 1998 1277 1281 (Pubitemid 128471479)
7. A. Cambi How C-type lectins detect pathogens Cell. Microbiol. 7 2005 481 488 (Pubitemid 40439447)
8. E.K. Jo Mycobacterial interaction with innate receptors: TLRs, C-type lectins, and NLRs Curr. Opin. Infect. Dis. 21 2008 279 286
9. P.J. Brennan, and H. Nikaido The envelope of mycobacteria Annu. Rev. Biochem. 64 1995 29 63
10. O. Neyrolles, and C. Guilhot Recent advances in deciphering the contribution of Mycobacterium tuberculosis lipids to pathogenesis Tuberculosis 91 2011 187 195
11. C. Astarie-Dequeker The role of mycobacterial lipids in host pathogenesis Drug Dis. Today: Dis. Mech. 7 2010 E33 E41
12. L. Jordao, and O.V. Vieira Tuberculosis: new aspects of an old disease Int. J. Cell Biol. 2011 Article ID 403623, DOI: 10.1155/2011/403623
13. C.L. Cosma The secret lives of the pathogenic mycobacteria Annu. Rev. Microbiol. 57 2003 641 676 (Pubitemid 37392957)
14. J.L. Flynn, and J. Chan Immune evasion by Mycobacterium tuberculosis: living with the enemy Curr. Opin. Immunol. 15 2003 450 455 (Pubitemid 36930083)
15. S. Gordon BCG-induced granuloma formation in murine tissues Immunobiology 191 1994 369 377 (Pubitemid 24331462)
16. J. Chan, and J. Flynn The immunological aspects of latency in tuberculosis Clin. Immunol. 110 2004 2 12 (Pubitemid 38177416)
17. S.H. Kaufmann Immunity to intracellular bacteria Annu. Rev. Immunol. 11 1993 129 163 (Pubitemid 23115004)
18. K. Dheda Lung remodeling in pulmonary tuberculosis J. Infect. Dis. 192 2005 1201 1209
19. D. Young Chronic bacterial infections: living with unwanted guests Nat. Immunol. 3 2002 1026 1032 (Pubitemid 35363653)
20. B.M. Saunders, and W.J. Britton Life and death in the granuloma: immunopathology of tuberculosis Immunol. Cell Biol. 85 2007 103 111 (Pubitemid 46398725)
21. J.G. Bartlett Tuberculosis and HIV infection: partners in human tragedy J. Infect. Dis. 196 Suppl. 1 2007 S124 S125
22. J.A. Armstrong, and P.D. Hart Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes J. Exp. Med. 134 1971 713 740
23. J. Pieters Mycobacterium tuberculosis and the macrophage: maintaining a balance Cell Host Microbe 3 2008 399 407 (Pubitemid 351773101)
24. S. Schüller Coronin is involved in uptake of Mycobacterium bovis BCG in human macrophages but not in phagosome maintenance Cell Microbiol. 3 2001 785 793 (Pubitemid 33133475)
25. I. Vergne Mycobacterium tuberculosis phagosome maturation arrest: selective targeting of PI3P-dependent membrane trafficking Traffic 4 2003 600 606 (Pubitemid 37062683)
26. 2+/calmodulin-PI3K hVPS34 cascade J. Exp. Med. 198 2003 653 659 (Pubitemid 37040399)
27. I. Vergne Mechanism of phagolysosome biogenesis block by viable Mycobacterium tuberculosis Proc. Natl Acad. Sci. U. S. A. 102 2005 4033 4038 (Pubitemid 40388550)
28. N. van der Wel M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells Cell 129 2007 1287 1298
29. K. Honer zu Bentrup, and D.G. Russell Mycobacterial persistence: adaptation to a changing environment Trends Microbiol. 9 2001 597 605 (Pubitemid 33135416)
30. L.E. Via Effects of cytokines on mycobacterial phagosome maturation J. Cell Sci. 111 1998 897 905
31. D.G. Russell Who puts the tubercle in tuberculosis? Nat. Rev. Microbiol. 5 2007 39 47 (Pubitemid 44942302)
32. R. Shegokar Present status of nanoparticle research for treatment of tuberculosis J. Pharm. Pharmaceut. Sci. 14 2011 100 116
33. A. Sosnik New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery Adv. Drug. Deliv. Rev. 62 2010 547 559
34. P. Blasi Fighting tuberculosis: old drugs new formulations Expert Opin. Drug Deliv. 6 2009 977 993
35. L.C. du Toit Tuberculosis chemotherapy: current drug delivery approaches Respir. Res. 7 2006 118
36. R. Pandey, and G.K. Khuller Nanotechnology based drug delivery system(s) for the management of tuberculosis Ind. J. Exp. Biol. 44 2006 357 366
37. D. Dube, and S.P. Vyas Nanocolloidal systems for macrophage targeting of therapeutics and diagnostics S.P. Vyas, Colloidal Nanocarriers: Site specific and Controlled Drug Delivery 1st edn. 2010 CBS Publishers 470 495
38. E. Briones Delivery systems to increase the selectivity of antibiotics in phagocytic cells J. Control. Release 125 2008 210 227
39. Z.P. Xu Inorganic nanoparticles as carriers for efficient cellular delivery Chem. Eng. Sci. 61 2006 1027 1040 (Pubitemid 41650188)
40. Y. Liu Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles Int. J. Cancer 120 2007 2527 2537 (Pubitemid 46651272)
41. M.N. Seleem Targeting Brucella melitensis with polymeric nanoparticles containing streptomycin and doxycycline FEMS Microbiol. Lett. 294 2009 24 31
42. M.A. Vladimirsky, and G.A. Ladigina Antibacterial activity of liposome-entrapped streptomycin in mice infected with Mycobacterium tuberculosis Biomed. Pharmacother. 36 1982 375 377 (Pubitemid 13120760)
43. S.P. Klemens Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice Antimicrob. Agents Chemother. 34 1990 967 970 (Pubitemid 20177336)
44. C.P. Jain, and S.P. Vyas Preparation and characterization of niosomes containing rifampicin for lung targeting J. Microencapsul. 12 1995 401 407
45. C.P. Jain Niosomal system for delivery of rifampicin to lymphatics Indian J. Pharm. Sci. 68 2006 575 578 (Pubitemid 46087763)
46. Y.V. Anisimova Nanoparticles as antituberculosis drugs carriers: effect on activity against Mycobacterium tuberculosis in human monocyte-derived macrophages J. Nanopart. Res. 2 2000 165 171 (Pubitemid 33230011)
47. F. Fawaz Ciprofloxacin-loaded polyisobutylcyanoacrylate nanoparticles: pharmacokinetics and in vitro anti-microbial activity Int. J. Pharm. 168 1998 255 259 (Pubitemid 28349966)
48. K.O. Kisich Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis Int. J. Pharm. 345 2007 154 162 (Pubitemid 350087550)
49. E.V. Shipulo Development of a nanosomal formulation of moxifloxacin based on poly (butyl-2-cyanoacrylate) Pharm. Chem. J. 42 2008 145 149
50. S. Kailasam Maintenance of therapeutically active levels of isoniazid for prolonged periods in rabbits after a single implant of biodegradable polymer Tuber. Lung Dis. 75 1994 361 365 (Pubitemid 24336533)
51. M. Dutt, and G.K. Khuller Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in poly (dl-lactide-co-glycolide) microparticles J. Antimicrob. Chemother. 47 2001 829 835 (Pubitemid 32519831)
52. R. Pandey Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis Tuberculosis 83 2003 373 378 (Pubitemid 37464042)
53. A. Zahoor Pharmacokinetic and pharmacodynamic behavior of antitubercular drugs encapsulated in alginate nanoparticles at two doses Int. J. Antimicrob. Agents 27 2006 409 416
54. R. Pandey Oral solid lipid nanoparticle-based antitubercular chemotherapy Tuberculosis 85 2005 415 420 (Pubitemid 41617396)
55. M.A. Moretton Synthesis and characterization of amphiphilic poly/epsilon-caprolactone-poly(ethyleneglycol) block copolymers. Optimization of the solubility and stability of rifampicin by means of encapsulation into polymeric micelles BIOOMAT 2009, I Workshop on Artificial Organs, Biomaterials and Tissue Engineering, Latin American Society of Biomaterials, Tissue Engineering and Artificial Organs (SLABO) Rosario, Argentina 2009
56. Z. Jiang Injectable hydrogels of poly(ε-caprolactone-coglycolide)- poly(ethylene glycol)-poly(ε-caprolactone-co glycolide) triblock copolymer aqueous solutions Polymer 48 2007 4786 4792 (Pubitemid 47069494)
57. Y. Jin Monolayers of the lipid derivatives of isoniazid at the air/water interface and the formation of self-assembled nanostructures in water Colloids Surf. B. Biointerfaces 64 2008 229 235
58. P. Deol, and G.K. Khuller Lung specific liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice Biochem. Biophys. Acta 1334 1997 161 172 (Pubitemid 27117518)
59. A. Sharma Lectin-functionalized poly (lactide-coglycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis J. Antimicrob. Chemother. 54 2004 761 766 (Pubitemid 39386728)
60. G.K. Saraogi Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis J. Drug Target. 19 2011 2192-2127
61. P.V. Kumar Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers J. Drug Target. 14 2006 546 556 (Pubitemid 44592888)
62. R. Pandey Poly (dllactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis J. Antimicrob. Chemother. 52 2003 981 986 (Pubitemid 38008419)
63. K. Ohashi One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis J. Control. Release 135 2009 19 24
64. P. O'Hara, and A.J. Hickey Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization Pharm. Res. 17 2000 955 961
65. L. Garcia-Contreras Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig J. Antimicrob. Chemother. 58 2006 980 986
66. S.P. Vyas Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages Int. J. Pharm. 269 2004 37 49 (Pubitemid 38035210)
67. N. Duzgunes Treatment of intracellular Mycobacterium avium complex infection by free and liposome encapsulated sparfloxacin Antimicrob. Agents Chemother. 40 1996 2618 2621 (Pubitemid 26367654)
68. S. Leitzke Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection Antimicrob. Agents Chemother. 42 1998 459 461 (Pubitemid 28114467)
69. R.T. Mehta In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and Mycobacterium tuberculosis Antimicrob. Agents Chemother. 37 1999 2584 2587
70. L.B. Adams Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine Antimicrob. Agents Chemother. 43 1999 1638 1643 (Pubitemid 29331240)
71. S. Labana Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes Int. J. Antimicrob. Agents 20 2002 301 304
72. M.S. El-Ridy Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis Int. J. Pharm. 330 2007 82 88 (Pubitemid 46097363)
73. M.M. Gaspar Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis Int. J. Antimicrob. Agents 31 2008 37 45 (Pubitemid 350245738)
74. P. Deol Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice Antimicrob. Agents Chemother. 41 1997 1211 1214 (Pubitemid 27231415)
75. S. Giovagnoli Unilamellar vesicles as potential capreomycin sulfate carriers: preparation and physicochemical characterization AAPS PharmSci Tech. 4 2003 E69
76. M. Ricci Development of liposomal capreomycin sulfate formulations: effects of formulation variables on peptide encapsulation Int. J. Pharm. 311 2006 172 181
77. S. Chono Uptake characteristics of liposomes by rat alveolar macrophages: influence of particle size and surface mannose modification J. Pharm. Pharmacol. 59 2007 75 80 (Pubitemid 46133045)
78. S. Chono Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections J. Control. Release 127 2008 50 58
79. W. Wijagkanalan Efficient targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes in rats J. Control. Release 125 2008 121 130 (Pubitemid 350299608)
80. A.R. Mullaicharam, and R.S.R. Murthy Lung accumulation of niosome-entrapped rifampicin following intravenous and intratracheal administration in the rat J. Drug Deliv. Sci. Technol. 14 2004 99 104 (Pubitemid 38506436)
81. M. Dutt, and G.K. Khuller Sustained release of isoniazid from a single injectable dose of poly (dl-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis Int. J. Antimicrob. Agents 17 2001 115 122 (Pubitemid 32101566)
82. Q. Ain Role of poly [dl-lactide-co-glycolide] in development of a sustained oral delivery system for antitubercular drug(s) Int. J. Pharm. 239 2002 37 46 (Pubitemid 34615793)
83. E.L.W. Barrow Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages Antimicrob. Agents Chemother. 42 1998 2682 2689 (Pubitemid 28462915)
84. S. Suarez Airways delivery of rifampicin microparticles for the treatment of tuberculosis J. Antimicrob. Chemother. 48 2001 431 434 (Pubitemid 32898818)
85. R. Pandey, and G.K. Khuller Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model J. Antimicrob. Chemother. 57 2006 1146 1152 (Pubitemid 44644418)
86. R. Pandey Chemotherapeutic efficacy of nanoparticle encapsulated antitubercular drugs Drug Deliv. 13 2006 287 294 (Pubitemid 43739140)
87. R. Pandey, and G.K. Khuller Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model J. Antimicrob. Chemother. 54 2004 266 268 (Pubitemid 39029006)
88. G.K. Saraogi Gelatin nanocarriers as potential vectors for effective management of tuberculosis Int. J. Pharm. 385 2010 143 149
89. M. Ahmed Potential of nanoemulsions for intravenous delivery of rifampicin Pharmazie 63 2008 806 811
90. C.M. Johnson Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis Antimicrob. Agents Chemother. 49 2005 4335 4338 (Pubitemid 41400981)
91. A. Zahoor Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis Int. J. Antimicrob. Agents 26 2005 298 303 (Pubitemid 41338657)
92. K. Hirota Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis J. Control. Release 142 2010 339 346
93. P. Muttil Inhalable microparticles containing large payload of anti-tuberculosis drugs Eur. J. Pharm. Sci. 32 2007 140 150 (Pubitemid 47285721)
94. H. Zhou Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages J. Control. Release 107 2005 288 299 (Pubitemid 41316291)
95. R. Sharma Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis Pharm. Res. 18 2001 1405 1410 (Pubitemid 32977245)
96. S.M. Hwang Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis J. Control. Release 129 2008 100 106
97. L. Chen Enantiomeric PLA-PEG block copolymers and their stereocomplex micelles used as rifampin delivery J. Nanopart. Res. 9 2007 777 785 (Pubitemid 46988301)
98. Y. Wu Polymeric micelle composed of PLA and chitosan as a drug carrier J. Polym. Res. 16 2009 11 18
99. M. Silva Potential tuberculostatic agents: micelle-forming copolymer poly(ethylene glycol)-poly(aspartic acid) prodrug with isoniazid Arch. Pharm. Pharm. Med. Chem. 334 2001 189 193 (Pubitemid 32612698)
100. M. Silva Potential tuberculostatic agent: micelle-forming pyrazinamide prodrug Arch. Pharm. Chem. Life Sci. 339 2006 283 290 (Pubitemid 43980042)
101. M. Silva Preparation of polymeric micelles for use as carriers of tuberculostatic drugs Trop. J. Pharm. Res. 6 2007 815 824
102. P.V. Kumar PEGylated dendritic architecture for development of a prolonged drug delivery system for an antitubercular drug Curr. Drug Deliv. 4 2007 11 19